|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ATM-ENPP2 (FusionGDB2 ID:7744) |
Fusion Gene Summary for ATM-ENPP2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ATM-ENPP2 | Fusion gene ID: 7744 | Hgene | Tgene | Gene symbol | ATM | ENPP2 | Gene ID | 472 | 5168 |
| Gene name | ATM serine/threonine kinase | ectonucleotide pyrophosphatase/phosphodiesterase 2 | |
| Synonyms | AT1|ATA|ATC|ATD|ATDC|ATE|TEL1|TELO1 | ATX|ATX-X|AUTOTAXIN|LysoPLD|NPP2|PD-IALPHA|PDNP2 | |
| Cytomap | 11q22.3 | 8q24.12 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine-protein kinase ATMA-T mutatedAT mutatedTEL1, telomere maintenance 1, homologataxia telangiectasia mutated | ectonucleotide pyrophosphatase/phosphodiesterase family member 2E-NPP 2autotaxin-textracellular lysophospholipase Dphosphodiesterase I/nucleotide pyrophosphatase 2plasma lysophospholipase D | |
| Modification date | 20200322 | 20200313 | |
| UniProtAcc | . | Q13822 | |
| Ensembl transtripts involved in fusion gene | ENST00000278616, ENST00000452508, ENST00000525178, | ENST00000259486, ENST00000427067, ENST00000522167, ENST00000522826, ENST00000075322, ENST00000518109, | |
| Fusion gene scores | * DoF score | 5 X 5 X 4=100 | 10 X 9 X 6=540 |
| # samples | 5 | 11 | |
| ** MAII score | log2(5/100*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(11/540*10)=-2.29545588352617 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ATM [Title/Abstract] AND ENPP2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ATM(108190785)-ENPP2(120650767), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | ATM-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. ATM-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. ATM-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. ATM-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. ATM-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. ATM-ENPP2 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. ATM-ENPP2 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ATM | GO:0006468 | protein phosphorylation | 15916964 |
| Hgene | ATM | GO:0006974 | cellular response to DNA damage stimulus | 9733515|16213212 |
| Hgene | ATM | GO:0010212 | response to ionizing radiation | 9733515|11375976 |
| Hgene | ATM | GO:0018105 | peptidyl-serine phosphorylation | 9733515|26323318 |
| Hgene | ATM | GO:0046777 | protein autophosphorylation | 9733515|15790808 |
| Hgene | ATM | GO:0071044 | histone mRNA catabolic process | 16086026 |
| Hgene | ATM | GO:0071480 | cellular response to gamma radiation | 9925639|16213212 |
| Hgene | ATM | GO:0071481 | cellular response to X-ray | 26323318 |
| Hgene | ATM | GO:0071500 | cellular response to nitrosative stress | 23878245 |
| Tgene | ENPP2 | GO:0009395 | phospholipid catabolic process | 15280042|26371182 |
| Tgene | ENPP2 | GO:0030149 | sphingolipid catabolic process | 14500380 |
| Tgene | ENPP2 | GO:0030334 | regulation of cell migration | 1733949 |
| Tgene | ENPP2 | GO:0034638 | phosphatidylcholine catabolic process | 21240271 |
| Tgene | ENPP2 | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 18054784 |
| Fusion gene breakpoints across ATM (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ENPP2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | OV | TCGA-13-0908-01B | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
Top |
Fusion Gene ORF analysis for ATM-ENPP2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000278616 | ENST00000259486 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| Frame-shift | ENST00000278616 | ENST00000427067 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000278616 | ENST00000522167 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000278616 | ENST00000522826 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000278616 | ENST00000075322 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000278616 | ENST00000518109 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| Frame-shift | ENST00000452508 | ENST00000259486 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| Frame-shift | ENST00000452508 | ENST00000427067 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000452508 | ENST00000522167 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000452508 | ENST00000522826 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000452508 | ENST00000075322 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| 5CDS-intron | ENST00000452508 | ENST00000518109 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| intron-3CDS | ENST00000525178 | ENST00000259486 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| intron-3CDS | ENST00000525178 | ENST00000427067 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| intron-intron | ENST00000525178 | ENST00000522167 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| intron-intron | ENST00000525178 | ENST00000522826 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| intron-intron | ENST00000525178 | ENST00000075322 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| intron-intron | ENST00000525178 | ENST00000518109 | ATM | chr11 | 108190785 | + | ENPP2 | chr8 | 120650767 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ATM-ENPP2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ATM-ENPP2 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | ENPP2 |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Hydrolyzes lysophospholipids to produce the signaling molecule lysophosphatidic acid (LPA) in extracellular fluids (PubMed:15769751, PubMed:26371182, PubMed:27754931, PubMed:14500380, PubMed:12354767,). Major substrate is lysophosphatidylcholine (PubMed:12176993, PubMed:27754931, PubMed:14500380). Also can act on sphingosylphosphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility (PubMed:14500380). Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP (PubMed:15769751, PubMed:12176993). Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation (PubMed:11559573). Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein (PubMed:1733949). May have a role in induction of parturition (PubMed:12176993). Possible involvement in cell proliferation and adipose tissue development (Probable). Tumor cell motility-stimulating factor (PubMed:1733949, PubMed:11559573). Required for LPA production in activated platelets, cleaves the sn-1 lysophospholipids to generate sn-1 lysophosphatidic acids containing predominantly 18:2 and 20:4 fatty acids (PubMed:21393252). Shows a preference for the sn-1 to the sn-2 isomer of 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) (PubMed:21393252). {ECO:0000269|PubMed:11559573, ECO:0000269|PubMed:12176993, ECO:0000269|PubMed:12354767, ECO:0000269|PubMed:14500380, ECO:0000269|PubMed:15769751, ECO:0000269|PubMed:1733949, ECO:0000269|PubMed:21240271, ECO:0000269|PubMed:21393252, ECO:0000269|PubMed:26371182, ECO:0000269|PubMed:27754931, ECO:0000305|PubMed:15700135}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ATM-ENPP2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for ATM-ENPP2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ATM-ENPP2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ATM-ENPP2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ATM | C0004135 | Ataxia Telangiectasia | 37 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | ATM | C0009405 | Hereditary Nonpolyposis Colorectal Neoplasms | 6 | CLINGEN |
| Hgene | ATM | C1112155 | Hereditary non-polyposis colorectal cancer syndrome | 6 | CLINGEN |
| Hgene | ATM | C1333990 | Hereditary Nonpolyposis Colorectal Cancer | 6 | CLINGEN |
| Hgene | ATM | C1333991 | Hereditary Non-Polyposis Colon Cancer Type 2 | 6 | CLINGEN |
| Hgene | ATM | C2936783 | Colorectal cancer, hereditary nonpolyposis, type 1 | 6 | CLINGEN |
| Hgene | ATM | C0346153 | Breast Cancer, Familial | 5 | CLINGEN |
| Hgene | ATM | C0033578 | Prostatic Neoplasms | 4 | CTD_human |
| Hgene | ATM | C0376358 | Malignant neoplasm of prostate | 4 | CTD_human |
| Hgene | ATM | C0023434 | Chronic Lymphocytic Leukemia | 2 | CTD_human;ORPHANET;UNIPROT |
| Hgene | ATM | C0030297 | Pancreatic Neoplasm | 2 | CTD_human |
| Hgene | ATM | C0346647 | Malignant neoplasm of pancreas | 2 | CTD_human |
| Hgene | ATM | C0005684 | Malignant neoplasm of urinary bladder | 1 | CGI;CTD_human |
| Hgene | ATM | C0005695 | Bladder Neoplasm | 1 | CGI;CTD_human |
| Hgene | ATM | C0006142 | Malignant neoplasm of breast | 1 | CTD_human;GENOMICS_ENGLAND |
| Hgene | ATM | C0006826 | Malignant Neoplasms | 1 | CTD_human |
| Hgene | ATM | C0007137 | Squamous cell carcinoma | 1 | CTD_human |
| Hgene | ATM | C0007193 | Cardiomyopathy, Dilated | 1 | CTD_human |
| Hgene | ATM | C0010606 | Adenoid Cystic Carcinoma | 1 | CTD_human |
| Hgene | ATM | C0016059 | Fibrosis | 1 | CTD_human |
| Hgene | ATM | C0017638 | Glioma | 1 | CGI;GENOMICS_ENGLAND |
| Hgene | ATM | C0021051 | Immunologic Deficiency Syndromes | 1 | GENOMICS_ENGLAND |
| Hgene | ATM | C0023418 | leukemia | 1 | CGI;GENOMICS_ENGLAND |
| Hgene | ATM | C0024299 | Lymphoma | 1 | CGI;GENOMICS_ENGLAND |
| Hgene | ATM | C0024623 | Malignant neoplasm of stomach | 1 | CGI;CTD_human |
| Hgene | ATM | C0025149 | Medulloblastoma | 1 | CGI;GENOMICS_ENGLAND |
| Hgene | ATM | C0025202 | melanoma | 1 | CTD_human |
| Hgene | ATM | C0027051 | Myocardial Infarction | 1 | CTD_human |
| Hgene | ATM | C0027651 | Neoplasms | 1 | CTD_human |
| Hgene | ATM | C0033054 | Prenatal Exposure Delayed Effects | 1 | CTD_human |
| Hgene | ATM | C0036341 | Schizophrenia | 1 | PSYGENET |
| Hgene | ATM | C0038356 | Stomach Neoplasms | 1 | CGI;CTD_human |
| Hgene | ATM | C0079773 | Lymphoma, T-Cell, Cutaneous | 1 | CTD_human |
| Hgene | ATM | C0079774 | Peripheral T-Cell Lymphoma | 1 | CTD_human |
| Hgene | ATM | C0086543 | Cataract | 1 | CTD_human |
| Hgene | ATM | C0086692 | Benign Neoplasm | 1 | CTD_human |
| Hgene | ATM | C0242698 | Ventricular Dysfunction, Left | 1 | CTD_human |
| Hgene | ATM | C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 1 | CGI;GENOMICS_ENGLAND;UNIPROT |
| Hgene | ATM | C0376407 | Granulomatous Slack Skin | 1 | CTD_human |
| Hgene | ATM | C0524524 | Pseudoaphakia | 1 | CTD_human |
| Hgene | ATM | C0555202 | Malignant lymphoma - lymphocytic, intermediate differentiation | 1 | ORPHANET |
| Hgene | ATM | C0855095 | Small Lymphocytic Lymphoma | 1 | ORPHANET |
| Hgene | ATM | C1449563 | Cardiomyopathy, Familial Idiopathic | 1 | CTD_human |
| Hgene | ATM | C1510497 | Lens Opacities | 1 | CTD_human |
| Hgene | ATM | C1623038 | Cirrhosis | 1 | CTD_human |
| Hgene | ATM | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| Hgene | ATM | C1843542 | T-CELL PROLYMPHOCYTIC LEUKEMIA, SOMATIC | 1 | GENOMICS_ENGLAND |
| Hgene | ATM | C1868683 | B-CELL MALIGNANCY, LOW-GRADE | 1 | ORPHANET |
| Hgene | ATM | C1876175 | Ataxia-Telangiectasia Variant | 1 | ORPHANET |
| Hgene | ATM | C2239176 | Liver carcinoma | 1 | CTD_human |
| Hgene | ATM | C2931456 | Prostate cancer, familial | 1 | CTD_human |
| Hgene | ATM | C4722327 | PROSTATE CANCER, HEREDITARY, 1 | 1 | CTD_human |
| Tgene | ENPP2 | C0005612 | Birth Weight | 1 | CTD_human |
| Tgene | ENPP2 | C0019158 | Hepatitis | 1 | CTD_human |
| Tgene | ENPP2 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | ENPP2 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| Tgene | ENPP2 | C0040136 | Thyroid Neoplasm | 1 | CTD_human |
| Tgene | ENPP2 | C0151468 | Thyroid Gland Follicular Adenoma | 1 | CTD_human |
| Tgene | ENPP2 | C0549473 | Thyroid carcinoma | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies